# JUBLPHARMA (JUBLPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/jublpharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,065.4
- Change: +5.27%
- As of: 2026-09-18
- 1D return: +5.27%
- 5D return: +3.88%
- 1M return: +22.31%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, JUBLPHARMA is trading at ₹1065.4, with a predominantly bullish technical stance on the daily and weekly timeframes, while the monthly timeframe indicates a bearish trend. Daily indicators show the price is above key moving averages including the 20-day EMA (₹971.24), 50-day EMA (₹952.96), and 200-day SMA (₹958.94), with a strong ADX of 29.53 suggesting an established trend. The weekly timeframe also shows the price above its 20-week EMA (₹957.29) and 50-week EMA (₹975.40), with a bullish Supertrend at ₹829.06. However, the monthly Supertrend is bearish at ₹1336.25, indicating potential longer-term headwinds. Recent anomalies include a high-severity upward wide intraday range on September 18, 2026, and a high-severity high participation, no clear direction event on the weekly chart on September 11, 2026. The stock is positioned 91% of the way up its 20-day and 50-day range, and 70% of its 252-day range, suggesting it is trading near the upper bounds of recent price action. The nearest support is observed at ₹1055.17, approximately 0.96% below the current price, while the nearest resistance is at ₹1101.02, about 3.34% higher. The stock exhibits an annualized volatility of 35% and a current drawdown of -14%.

- Daily and weekly timeframes show bullish price action above key moving averages.
- Monthly timeframe shows a bearish Supertrend at ₹1336.25.
- Nearest support level identified at ₹1055.17.
- Nearest resistance level identified at ₹1101.02.
- Watch for a break above ₹1101.02 to test higher resistance, or a fall below ₹1055.17 to test further support.

- Hammer
- Bullish Engulfing Reversal
- Bearish Engulfing Reversal
- Evening Star
- Outside Bar
- Harami

### What Changed

As of the observation date September 18, 2026, Jubilant Pharmova (JUBLPHARMA) on the NSE has seen its stock price increase to ₹1065.4 from a previous price of ₹1012.1. The company's profile and exchange listing remain unchanged from earlier context. There are no new filings or news developments reported as of this date.

- Stock price increased to ₹1065.4 as of September 18, 2026, from ₹1012.1 previously.
- Company remains listed on the NSE.
- No new filings or news were reported as of September 18, 2026.

### Official Filings

Jubilant Pharmova Limited and its subsidiary have disclosed receipt of Show Cause Notices related to Goods and Services Tax (GST) liabilities. Jubilant Pharmova Limited received a notice on August 31, 2026, from Mysore authorities concerning alleged GST liabilities for the financial year 2022–2023, proposing a demand of ₹87.31 crore, including tax, interest, and penalty. Separately, on August 28, 2026, Jubilant Generics Limited, a wholly-owned subsidiary, received a notice from Uttarakhand CGST Division for alleged inadmissible IGST refunds during FY 2020-21 and 2021-22, proposing a GST demand of ₹52.75 crore plus an equal penalty. In both instances, the companies stated their intention to file detailed replies contesting the notices, asserting they are factually incorrect and expecting no financial or operational impact.

In other developments, the company held its 48th Annual General Meeting on August 26, 2026, where all resolutions were passed, including the declaration of a dividend of ₹5 per equity share for the financial year ended March 31, 2026. The meeting also saw the adoption of audited financial statements for FY 2025-26, during which consolidated revenue growth of 14% to ₹83 billion was highlighted. Additionally, on August 17, 2026, shareholders approved through postal ballot the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, along with their remuneration.

- On August 31, 2026, Jubilant Pharmova Limited received a Show Cause Notice proposing a GST demand of ₹87.31 crore for FY 2022-23, which the company intends to contest.
- On August 28, 2026, Jubilant Generics Limited received a Show Cause Notice proposing a GST demand of ₹52.75 crore plus penalty for FY 2020-21 and 2021-22, which the subsidiary intends to contest.
- The company declared a dividend of ₹5 per equity share for the financial year ended March 31, 2026, at its AGM on August 26, 2026.
- On August 26, 2026, the company adopted audited standalone and consolidated financial statements for FY 2025-26, reporting consolidated revenue growth of 14% to ₹83 billion.
- Shareholders approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director via postal ballot results announced on August 17, 2026.

- Jubilant Pharmova Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Jubilant Pharmova Limited has informed the Exchange about General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST |SUBJECT: General Updates
- Jubilant Pharmova Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- MEETING DATE : 26-AUG-2026
- Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 26, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
- Jubilant Pharmova Limited has informed the Exchange about General Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A |SUBJECT: General Updates
- Jubilant Pharmova Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 10-Aug-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended June 2026 . |SUBJECT: Board Meeting Intimation

### Fundamentals

Jubilant Pharmova reported revenue from operations of ₹2,229.40 crore in Q1 FY2026-27. This follows revenues of ₹2,122.50 crore in Q3 FY2025-26 and ₹2,290 crore in Q4 FY2025-26. Profit Before Tax (PBT) for Q1 FY2026-27 was ₹86.40 crore, compared to ₹93.50 crore in Q3 FY2025-26 and ₹176 crore in Q4 FY2025-26. The net profit, or Profit Loss For Period, was ₹56.40 crore in Q1 FY2026-27, down from ₹55.80 crore in Q3 FY2025-26 and ₹119.30 crore in Q4 FY2025-26. Finance costs remained relatively stable, reported at ₹54.20 crore in Q1 FY2026-27, ₹56.10 crore in Q3 FY2025-26, and ₹56.50 crore in Q4 FY2025-26. Tax expenses were ₹30 crore in Q1 FY2026-27, compared to ₹37.60 crore in Q3 FY2025-26 and ₹56.70 crore in Q4 FY2025-26. Other expenses increased sequentially from ₹410.30 crore in Q3 FY2025-26 to ₹479.20 crore in Q1 FY2026-27.

Key areas to monitor include the trend in revenue, particularly the sequential performance from Q4 FY2025-26 to Q1 FY2026-27, and the factors influencing profitability. The increase in 'Other Expenses' from ₹410.30 crore in Q3 FY2025-26 to ₹479.20 crore in Q1 FY2026-27 warrants attention as it impacts the bottom line.

- Revenue from operations stood at ₹2,229.40 crore in Q1 FY2026-27.
- Profit Before Tax (PBT) was ₹86.40 crore in Q1 FY2026-27.
- Net profit for Q1 FY2026-27 was ₹56.40 crore.
- Finance costs were ₹54.20 crore in Q1 FY2026-27.
- Other expenses increased to ₹479.20 crore in Q1 FY2026-27 from ₹410.30 crore in Q3 FY2025-26.

### Bull Case

Jubilant Pharmova's technical indicators suggest a constructive short-to-medium term outlook. The daily trend analysis shows the closing price of ₹1065.4 is above its 20-day Exponential Moving Average (EMA) of ₹971.24 and its 50-day EMA of ₹952.96. The 20-day EMA is also trending upwards, indicated by a positive slope of 35.04 over 5 periods. The Supertrend indicator on the daily chart is bullish at ₹939.38, further supporting a positive short-term view. On a weekly basis, the Supertrend is also bullish at ₹829.06, with the closing price above both the 20-day EMA (₹957.29) and 50-day EMA (₹975.4). The stock has demonstrated positive returns over several shorter periods, including a 23% return in the last month and a 24% return over the last six months, although it has seen a 4% decline over the past year.

- As of September 18, 2026, Jubilant Pharmova's daily Supertrend indicator is bullish at ₹939.38.
- The stock's closing price of ₹1065.4 on September 18, 2026, is above its 20-day EMA (₹971.24) and 50-day EMA (₹952.96).
- The weekly Supertrend indicator is bullish at ₹829.06 as of September 18, 2026.
- The stock has generated a 23% return in the last month and a 24% return over the last six months, ending September 18, 2026.

- Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma
- Stocks to Watch for September 15: HDFC Bank, BSE, IT Stocks, Coforge, Tata Chemicals and more

### Bear Case

The company's monthly trend analysis indicates a bearish Supertrend reading at ₹1336.25, suggesting potential downward pressure over a longer timeframe. While the daily trend shows a bullish Supertrend at ₹939.38, the significant difference between these readings and the current closing price of ₹1065.4 highlights a divergence. The stock has experienced a drawdown of -14% from its recent peak and a maximum drawdown of -35%, indicating historical volatility. Over the past year, the stock has returned -4%, contrasting with positive returns over shorter periods like 1-month (+23%) and 6-months (+24%).

- The monthly trend Supertrend indicator is bearish at ₹1336.25 as of 2026-09-18.
- The stock has experienced a current drawdown of -14% and a maximum drawdown of -35%.
- The 1-year return as of 2026-09-18 was -4%, while 1-month and 6-month returns were +23% and +24% respectively.

- Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma
- Stocks to Watch for September 15: HDFC Bank, BSE, IT Stocks, Coforge, Tata Chemicals and more

### FAQs

**What are the recent tax-related notices received by Jubilant Pharmova and its subsidiary, and what is the company's stated position?**

Jubilant Pharmova Limited received a Show Cause Notice on August 31, 2026, from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, concerning alleged GST liabilities for the financial year 2022-2023. The notice proposes a total demand of ₹87.31 crore, including tax, interest, and penalty. Separately, on August 27, 2026, Jubilant Generics Limited, a wholly-owned subsidiary, received a Show Cause Notice from the CGST Division, Uttarakhand, proposing a GST demand of ₹52.75 crore plus an equal penalty for alleged inadmissible IGST refunds during FY 2020-21 and 2021-22. In both instances, the company stated its intention to file detailed replies contesting the notices, asserting they are factually incorrect and expecting no financial or operational impact.

**What were the key outcomes of Jubilant Pharmova's Annual General Meeting (AGM) held on August 26, 2026?**

At the 48th AGM on August 26, 2026, Jubilant Pharmova Limited passed all four resolutions. These included the declaration of a dividend of ₹5 per equity share for the financial year ended March 31, 2026, and the re-appointment of directors Mr. Hari S. Bhartia and Mr. Arjun Shanker Bhartia. The company also adopted audited standalone and consolidated financial statements for FY 2025-26. During the meeting, Chairman Shyam Sunder Bhartia reported consolidated revenue growth of 14% to ₹83 billion in FY26 and mentioned strategic progress on new manufacturing lines at the Spokane facility.

**How has Jubilant Pharmova's stock performed over different recent periods?**

As of September 18, 2026, Jubilant Pharmova's stock has shown varied returns across different periods. It has returned 23% in the last month and 24% in the last six months. Over the last year, the stock has seen a return of -4%. Looking at longer timeframes, the return over the last 10 years was 17%, and since the start of trading, it was -1%.

**What are the current technical indicators suggesting about Jubilant Pharmova's stock trend?**

On a daily timeframe as of September 18, 2026, technical indicators suggest a bullish trend, with the Supertrend indicator at 939.38 and a 'bullish' direction. The closing price of ₹1065.4 is above both the 20-day Exponential Moving Average (EMA) of 971.24 and the 50-day EMA of 952.96. However, on a monthly timeframe, the Supertrend indicator is at 1336.25 with a 'bearish' direction, indicating a different trend over a longer period.

- Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma
- Stocks to Watch for September 15: HDFC Bank, BSE, IT Stocks, Coforge, Tata Chemicals and more
- Jubilant Pharmova Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Jubilant Pharmova Limited has informed the Exchange about General Updates - Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST |SUBJECT: General Updates
- Jubilant Pharmova Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- MEETING DATE : 26-AUG-2026
- Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 26, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results. |SUBJECT: Shareholders meeting
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Weak Uptrend
- Pivot point: ₹1,011.68
- Risk regime: Price Risk Currently Contained

### Support levels
- 910.5703125
- 882.175
- 846.6078125

### Resistance levels
- 1101.01796875
- 1168.2
- 1185.875

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +5.27% |
| return_10 | +17.35% |
| return_1m | +23.03% |
| return_1y | -4.46% |
| return_20 | +22.31% |
| return_3m | +9.45% |
| return_5 | +3.88% |
| return_6m | +24.38% |
| return_since_start | -1.34% |
| return_ytd | +0.69% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -34.67% |
| annualized_volatility | +35.14% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Profit Falls 45% as Expenses Outpace Revenue Growth; Comprehensive Income Slumps on OCI Swing

Jubilant Pharmova Limited reported a 17% year-on-year increase in revenue to ₹2,229.40 crore in the first quarter of FY2026‑27, but profit before tax fell 44% to ₹86.40 crore and net profit declined 45% to ₹56.40 crore. Other expenses rose 19%, outpacing revenue growth, while a sharp negative swing in other comprehensive income caused total comprehensive income to drop 74% year-on‑year.

## Revenue Performance

Revenue from operations was ₹2,229.40 crore, up 17.3% from ₹1,900.70 crore in Q1 FY2025‑26. On a sequential basis, revenue declined 2.6% from ₹2,290 crore in the immediately preceding quarter (Q4 FY2025‑26).

## Profitability and Margins

Profit before tax fell to ₹86.40 crore, down 44.1% year‑on‑year from ₹154.50 crore and 50.9% from ₹176 crore sequentially. Net profit showed a similarly steep decline, dropping to ₹56.40 crore — 45% below the prior‑year quarter and 52.7% below the preceding quarter.

The profit‑before‑tax margin contracted to 3.9% from 8.1% in Q1 FY2025‑26. The effective tax rate (tax expense as a percentage of profit before tax) rose to 34.7% from 33.6% a year earlier and 32.2% in Q4, contributing modestly to the lower net profit.

## Expense Trends

Other expenses, a major cost item, increased 19.3% year‑on‑year to ₹479.20 crore from ₹401.80 crore. As a percentage of revenue, other expenses moved from 21.1% to 21.5%, absorbing a slightly larger share of sales. Sequentially, they edged up 1.8% from ₹470.50 crore.

Finance costs were ₹54.20 crore, 10.6% higher than ₹49 crore in Q1 FY2025‑26, though they were 4.1% lower than the ₹56.50 crore recorded in the preceding quarter. The year‑on‑year increase added to the expense burden.

## Other Comprehensive Income Swing

Other comprehensive income turned negative at –₹19.10 crore, compared with a positive ₹41.10 crore in the year‑earlier quarter and ₹281.90 crore in Q4. This swing drove total comprehensive income down to ₹37.30 crore, a decline of 74% from ₹143.60 crore year‑on‑year and 91% from ₹401.20 crore sequentially.

## Earnings Per Share

Basic earnings per share fell to ₹3.57, down 45% from ₹6.49 in Q1 FY2025‑26 and 53% from ₹7.55 in Q4. Diluted EPS moved similarly, to ₹3.56.

## Key Takeaway

Revenue grew 17% year‑on‑year, but profit fell sharply because expense increases — notably a 19% rise in other expenses — outpaced revenue growth. The quarter’s result was further reduced by a large negative swing in other comprehensive income, highlighting the combined effect of rising operating costs and non‑operating volatility on overall profitability.

### Ratios

## Official filings

- 2026-09-11 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_11092026194009_SE_USFDA_September_2026-final_signed.pdf)
- 2026-09-01 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_01092026124717_JPM_GSTNotice.pdf)
- 2026-08-28 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_28082026101506_PharmovaStockExchangeDisclosure.pdf)
- 2026-08-26 — Regulatory Filing: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1718219_26082026081342_WEB.xml)
- 2026-08-26 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_26082026200830_JPM_AGM_Proceedings_and_Scrutinizer_Report_2026_signed_f.pdf)
- 2026-08-22 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_23082026004902_USFDA_Intimation_August23.pdf)
- 2026-08-17 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_17082026211147_FinalPB.pdf)
- 2026-08-11 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_11082026182427_Intimation_-_Financial_in_Newspaper_signed.pdf)
- 2026-08-05 — Generic Announcement: Jubilant Pharmova Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_631_WebXMLFile_20260805_165000761.xml)
- 2026-08-05 — Generic Announcement: Jubilant Pharmova Limited will hold meetings with institutional investors including HDFC AMC, ICICI Prudential AMC, and Tata Asset Management on August 13-14, 2026, in Mumbai. These meetings, organized by Emkay Global Financial Services, will discuss the Q1 FY27 Earnings presentation, which will be filed on August 10, 2026, following the disclosure of Q1 FY27 financial results. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_05082026165919_IntimationofInvestorsAnalystsMeetin13082026signed.pdf)
- 2026-08-02 — Generic Announcement: Jubilant Pharmova Limited published newspaper advertisements on August 2, 2026, announcing the completion of email dissemination of the 48th Annual General Meeting notice and the Annual Report for FY 2025-26 on August 1, 2026. The advertisements also included e-voting information for the Annual General Meeting. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_02082026230827_PostDispatchAGMNotice2026signed.pdf)
- 2026-08-01 — Generic Announcement: Jubilant Pharmova Limited dispatched letters to shareholders without registered email addresses, providing weblinks to access the Annual Report for FY 2025-26 and the Notice for the 48th Annual General Meeting (AGM). The AGM is scheduled for August 26, 2026, and will be conducted via Video Conferencing or Other Audio Visual Means. Shareholders are encouraged to update their email addresses for electronic communication. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_01082026224932_SEintimationNonemailcasessigned.pdf)
- 2026-08-01 — Generic Announcement: Jubilant Pharmova Limited has announced its 48th Annual General Meeting (AGM) will be held on August 26, 2026, via Video Conferencing. The company will consider the Audited Financial Statements for FY 2025-26 and a proposed dividend of ₹5 per equity share. The AGM notice and Annual Report for FY 2025-26 were dispatched to members registered as of July 24, 2026. Remote e-voting will be open from August 23 to August 25, 2026, with a cut-off date of August 19, 2026, for voting eligibility. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_01082026223715_JPMAGMNoticeAnnualReport2026_mergedsigned.pdf)
- 2026-08-01 — Generic Announcement: Jubilant Pharmova Limited is informing shareholders about the deduction of tax at source (TDS) on the final dividend for FY 2025-26, recommended at ₹5 per equity share. Shareholders must submit necessary documentation, including PAN details and specific forms, by August 14, 2026, to avail beneficial tax rates or exemptions. Failure to provide required documents may result in TDS at higher rates, with specific procedures outlined for resident and non-resident shareholders. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_01082026225930_TDSDeductionintimationtoshareholdersSigned.pdf)
- 2026-07-30 — Official Filing: Jubilant Pharmova Limited will hold a board meeting on August 7, 2026, to consider its unaudited standalone and consolidated financial results for the quarter ended June 2026. The trading window for the company's securities will be closed from July 1, 2026, to August 9, 2026.
- 2026-07-30 — Generic Announcement: Jubilant Pharmova Limited published newspaper advertisements on July 30, 2026, in Financial Express, Hindustan, and Jansatta regarding the transfer of equity shares and dividend to the Investor Education and Protection Fund Authority. The company has made this information available on its website. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_30072026185602_Submissionofcopiesofnewspapersignedfinal.pdf)
- 2026-07-29 — Generic Announcement: Jubilant Pharmova Limited is notifying shareholders about the upcoming transfer of unpaid dividends and equity shares to the Investor Education and Protection Fund (IEPF). Dividends for the financial year 2018-19, and potentially subsequent years, are due for transfer to the IEPF on October 31, 2026, if unclaimed. Shareholders are urged to claim their unpaid dividends and equity shares by August 31, 2026, by contacting Alankit Assignments Limited. Failure to claim by this date will result in the transfer of shares and dividends to the IEPF, after which claims must be made directly to the IEPF Authority. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_29072026195512_Communicationtoshareholdersnoticeoftransfer.pdf)
- 2026-07-29 — Generic Announcement: Jubilant Pharmova Limited will hold its 48th Annual General Meeting on August 26, 2026, at 11:00 AM IST via Video Conferencing. The Notice of the AGM and the Annual Report for the 2025-26 financial year will be sent to shareholders and published on the company website. Newspaper advertisements regarding the AGM were published on July 29, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_29072026163147_Predispatch_AGM_Advertisement.pdf)
- 2026-07-19 — Generic Announcement: Jubilant Pharmova Limited has submitted copies of newspaper advertisements published on July 19, 2026, in Financial Express, Hindustan, and Jansatta, confirming the completion of dispatch of notices for a Postal Ballot. This disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_19072026182109_LetterNewspaperPB19july2026signed.pdf)
- 2026-07-18 — Generic Announcement: Jubilant Pharmova Limited is seeking shareholder approval via postal ballot for the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, both for a three-year term from June 1, 2026, to May 31, 2029. The company has initiated the postal ballot process, with remote e-voting open from July 19, 2026, to August 17, 2026. The results will be announced within two working days of the e-voting conclusion. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_18072026193631_PostalBallotDispatch18072026FinalSigned.pdf)
- 2026-07-18 — Official Filing: Jubilant Pharmova Limited announced a postal ballot for shareholders on July 18, 2026, to vote on two special resolutions. The resolutions concern the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, both with tenures from June 1, 2026, to May 31, 2029. The postal ballot voting ends on August 17, 2026, which is also the date of the shareholders meeting.
- 2026-07-16 — Generic Announcement: On July 16, 2026, Jubilant Pharmova Limited's Nomination, Remuneration and Compensation Committee approved the grant of 2,07,003 stock options, RSUs, or PSUs to eligible employees under the 2018 Stock Option Plan. The grant includes 1,81,570 options/RSUs/PSUs with an exercise price of Re. 1 and 25,433 stock options with an exercise price of Rs. 974.45. Vesting schedules vary, with some tied to performance over three years and others to specific dates or phased vesting over up to five years from the grant date. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_16072026183030_ESOP_Disclosure_signed.pdf)
- 2026-07-16 — Generic Announcement: Jubilant Pharmova Limited received a rectification order from the Income Tax Department on July 15, 2026, deleting the entire tax demand of Rs. 22.10 crores for Assessment Year 2020-21. The company is separately pursuing an appeal on merit grounds before the ITAT. This follows a prior disclosure on December 31, 2025, regarding tax demands. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_16072026134702_Disclosure16072026.pdf)
- 2026-07-02 — Generic Announcement: Jubilant Pharmova Limited has submitted a confirmation certificate for the quarter ended June 30, 2026, as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate was received from their Registrar and Share Transfer Agent, Alankit Assignments Limited. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_02072026132123_IntimationReg745signedQ1.pdf)
- 2026-07-01 — Generic Announcement: Jubilant Pharmova Limited published newspaper advertisements on June 30, 2026, in Financial Express, Hindustan, and Jansatta regarding a special window for re-lodging transfer requests of physical shares, KYC updation, dematerialization of physical share certificates, and the second 100-day IEPF Campaign “Saksham Niveshak”. — [Official attachment](https://nsearchives.nseindia.com/corporate/JUBLPHARMA_01072026182527_Covering_letter_-_Newspapesigned.pdf)

## News and market events

- 2026-09-15 — BUSINESS: **Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma** — Securities in F&O Ban: — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-lalithaa-jewellery-mart-hdfc-bank-kec-international-aurobindo-pharma-126091500114_1.html)
- 2026-09-14 — CNBC-TV18: **Stocks to Watch for September 15: HDFC Bank, BSE, IT Stocks, Coforge, Tata Chemicals and more** — From HDFC Bank's succession plan to Tata Sons' potential listing and its impact on listed Tata Group stocks and the impact of SEBI's consultation paper on CAS on BSE, Angel One and other brokers, these are the stocks you should watch out for going into Tuesday's trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-september-15-hdfc-bank-bse-angel-one-tata-group-infosys-tcs-raymond-share-price-19989980.htm)
- 2026-09-11 — CNBC-TV18: **Jubilant Pharmova's US CMO facility gets 'Voluntary Action Indicated' classification** — Shares of Jubilant Pharmova Ltd ended at ₹1,025.65, down by ₹0.050, or 0.0049%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/jubilant-pharmova-share-price-us-cmo-facility-gets-voluntary-action-indicated-classification-19989636.htm)
- 2026-09-08 — Mint: **Raja Venkatraman recommends three stocks for 8 September** — Market expert Raja Venkatraman shares his top stock picks for 8 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-8-september-11788800507147.html)
- 2026-08-28 — Economic Times: **Jubilant Generics receives show-cause notice demanding over Rs 105 cr** — Jubilant Generics received a Rs 105.5 crore GST show-cause notice from Uttarakhand authorities. The notice alleges improper availment of tax refund and Advance Authorisation Scheme benefits. This action pertains to the fiscal years 2020-21 and 2021-22. The company plans to contest the notice and file a detailed reply soon. Jubilant Pharmova expects no significant financial or operational impact. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jubilant-generics-receives-show-cause-notice-demanding-over-rs-105-cr/articleshow/133588367.cms)
- 2026-08-24 — MONEYCONTROL: **Buzzing Stocks: Meesho shares slip on block deal; Apollo Tyres gains 2% after UBS upgrade to ‘buy’** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/buzzing-stocks-meesho-shares-slip-on-block-deal-apollo-tyres-gains-2-after-ubs-upgrade-to-buy-14013468.html)
- 2026-08-24 — Economic Times: **Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra** — Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover... — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-reliance-industries-bank-of-baroda-power-grid-natco-pharma-and-jsw-infra/articleshow/133444199.cms)
- 2026-08-23 — CNBC-TV18: **Stocks to Watch for August 24: Reliance Industries, NATCO Pharma, Bank of Baroda** — RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-24-reliance-industries-natco-pharma-bank-of-baroda-federal-bank-jubilant-pharmova-apollo-micro-systems-19974715.htm)
- 2026-08-11 — CNBC-TV18: **Gland Pharma to Triveni Turbines: Top stocks to track in trade today** — Today, at market open, some Nifty 500 stocks rallied on strong earnings and bullish brokerage calls, while others slid on weak Q1 numbers. Here's a look at today's top gainers and losers at market open. — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-market-open-gland-pharma-jubilant-pharmova-kec-oil-india-19966195.htm)
- 2026-08-11 — MONEYCONTROL: **Jubilant Pharmova shares in focus on mixed Q1 earnings** — Jubilant Pharmova,Jubilant Pharmova share price,Jubilant Pharmova share price live today — [Source](https://www.moneycontrol.com/news/business/markets/jubilant-pharmova-shares-in-focus-on-mixed-q1-earnings-14000617.html)
- 2026-08-10 — CNBC-TV18: **Stocks to Watch for August 11: Vodafone Idea, Bharat Electronics, Gland Pharma, Bosch and more** — From BEL securing additional orders worth ₹541 crore to Lloyds Metals & Energy, KEC International, Vodafone Idea and others reporting their June-quarter results after market hours, these are the stocks likely to remain in focus ahead of Tuesday’s trading session. Ashiana Housing, Allcargo Terminals, Kalyani Forge and others are also due to report results on August 11. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-11-vodafone-idea-bharat-electronics-lloyds-metals-bosch-and-more-19965863.htm)
- 2026-08-10 — CNBC-TV18: **Jubilant Pharmova Q1 profit falls 45% as margins come under pressure** — Jubilant Pharmova’s June quarter profit dropped 45% year-on-year to ₹56.4 crore, even as revenue from operations climbed 17.3% to ₹2,229.4 crore. EBITDA fell 14.4% to ₹248 crore, while EBITDA margin narrowed to 11.1% from 15.2% a year earlier, weighing on the company’s bottom line. — [Source](https://www.cnbctv18.com/market/jubilant-pharmova-q1-profit-falls-45-pc-as-margins-come-under-pressure-19965969.htm)
- 2026-07-16 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today - 16 July 2026** — The Indian stock market ended Wednesday's session on a higher note. Sumeet Bagadia of Choice Broking recommends five breakout stocks to buy today. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-16-july-2026-11784134080670.html)

## Business profile

**Strategic vision:** Integrated global pharmaceutical company with diverse business segments.

### Business segments
- **Radiopharma:** The Radiopharma business segment is involved in the manufacturing and supply of radiopharmaceuticals, operating a network of 46 radio-pharmacies across the United States.
- **Allergy Immunotherapy:** This segment focuses on the manufacturing and supply of allergic extracts and venom products, supplied to markets in the United States, Canada, Europe, and Australia.
- **CDMO Sterile Injectables:** The company provides manufacturing services for sterile fill and finish injectables, including liquid and lyophilization forms, and an ophthalmic portfolio.
- **Contract Research Development and Manufacturing Organisation (CRDMO):** The CRDMO business integrates Drug Discovery Services and CDMO-API operations, providing contract research and development and manufacturing of Active Pharmaceutical Ingredients.
- **Generics:** The Generics business segment is involved in the manufacturing and supply of generic pharmaceutical products.
- **Proprietary Novel Drugs:** Jubilant Therapeutics, part of this business, is a biopharmaceutical company focused on developing therapies for oncology and auto-immune disorders.

### Competitive strengths
- Global presence with manufacturing facilities in regulated markets.
- Integrated operations across multiple pharmaceutical business segments.
- Network of radio-pharmacies across the United States.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.25%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.78%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.80%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +2.21%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — +0.12%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/jublpharma
Markdown representation: https://faxioms.com/stocks/jublpharma?render=md